The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review.
Recombinant human erythropoietin (rhEPO) has been used clinically to alleviate cancer- and chemotherapy-related anemia. However, recent clinical trials have reported that rhEPO also may adversely impact disease progression and survival. The expression of functional EPO receptors (EPOR) has been demonstrated in many human cancer cells where, at least in vitro, rhEPO can stimulate cell growth and survival and may induce resistance to selected therapies. Responses to rhEPO measured by alterations in tumor cell growth or survival, activation of signaling pathways or modulation of sensitivity to anticancer agents are variable. Both methodological and inherent biological issues underlie the differential cell responses, including reported difficulties in EPOR protein detection, potential involvement of EPOR isoforms or of cytoplasmic EPOR, possible differential structure and/or binding affinities of hematopoietic versus non-hematopoietic cell EPOR, possible aberrant regulation of EPOR activity, and a functional EPO/EPOR autocrine/paracrine loop. The modulation by rhEPO of tumor cell response to anticancer agents is coincident with modulation of multiple signaling pathways, BCL-2 family proteins, caspases and NFkB. The molecular interplay of pro-survival and pro-death signals, triggered by EPO and/or by anticancer agents, is multifactorial and tightly coordinated. Expression microarray analysis may prove critical for deciphering this potentially novel network and its broad spectrum of genes and proteins.
Szenajch
Jolanta
J
Laboratory for Molecular Oncology, Military Institute of Medicine, Warsaw, Poland.
Wcislo
Gabriel
G
Jeong
Jee-Yeong
JY
Szczylik
Cezary
C
Feldman
Laurie
L
D000818:Animals; D049109:Cell Proliferation; D002470:Cell Survival; D019008:Drug Resistance, Neoplasm; D004921:Erythropoietin / Q000737:chemistry / Q000502:physiology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D017467:Receptors, Erythropoietin / Q000737:chemistry / Q000502:physiology*; D015398:Signal Transduction
D017467:Receptors, Erythropoietin; D004921:Erythropoietin